Alemtuzumab in chronic lymphocytic leukemia

Future Oncology

Volumn 3, Issue 1, 2007, Pages 29-42

  James, Danelle F ^a   Kipps, Thomas J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alemtuzumab; Campath; CD52; Chronic lymphocytic leukemia; Monoclonal antibody

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALKYLATING AGENT; ANTIHISTAMINIC AGENT; CD52 ANTIGEN; CHLORAMBUCIL; CLOTRIMAZOLE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; FAMCICLOVIR; FLUCONAZOLE; FLUDARABINE; GLYCOPROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL; ITRACONAZOLE; LAMIVUDINE; PARACETAMOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GROWTH FACTOR; RITUXIMAB; VALACICLOVIR;

ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BONE MARROW; BONE MARROW TOXICITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DYSPNEA; FEVER; FOOD AND DRUG ADMINISTRATION; GENE TARGETING; GOVERNMENT REGULATION; HEPATITIS B; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; INFECTION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LARGE CELL LYMPHOMA; LEUKEMIA CELL; LYMPHADENOPATHY; LYMPHOCYTE DEPLETION; LYMPHOCYTOPENIA; MINIMAL RESIDUAL DISEASE; MYCOSIS; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGOR; SPLEEN; THROMBOCYTOPENIA; TREATMENT DURATION; UNITED STATES; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; SURVIVAL ANALYSIS;

EID: 33847072269     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.1.29     Document Type: Article

References (58)

1. Waldmann GHAH: From laboratory to clinic: the story of CAMPATH-1. Diagnostic and therapeutic antibodies. In: Methods in Molecular Medicine. Urch AGAC (Ed.). Humana Press, Totowa, NJ, USA 40, 243-266 (2000).
2. Hale G: The CD52 antigen and development of the CAMPATH antibodies. Cytotheraphy 3, 137-143 (2001).
3. Waldmann, H, Hale G: CAMPATH: from concept to clinic. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 360, 1707-1711 (2005).
4. Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB: Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J. Clin. Pathol. 47, 313-317 (1994).
5. Gilleece MH, Dexter TM: Effect of Campath- 1H antibody on human hematopoietic progenitors in vitro. Blood 82, 807-812 (1993).
6. Fabian I, Flidel O, Gadish M, Kletter Y, Slavin S, Nagler A: Effects of CAMPATH-1 antibodies on the functional activity of monocytes and polymorphonuclear neutrophils. Expr. Hematol. 21, 1522-1527 (1993).
7. Elsner J, Hochstetter R, Spickermann K, Kapp A: Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 88, 4684-4693 (1996).
8. Albitar M, Do KA, Johnson MM et al: Free circulating soluble CD52 as a tumor market in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 101, 999-1008 (2004).
9. Dyer MJHG, Hayhoe FG, Waldmann H: Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73, 1431-1439 (1989).
10. James LC, Hale G, Waldmann H, Bloomer AC: 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen. J. Mol. Biol. 289, 293-301 (1999).
11. Hutchins JT, Kull FC Jr, Bynum J, Knick VC, Thurmond LM, Ray P: Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H. Proc. Natl Acad. Sci. USA 92, 11980-11984 (1995).
12. Riechmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies for therapy. Nature 332, 323-327 (1988).
13. Lim SH, Davey G, Marcus R: Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma. Lancet 341, 432-433 (1993).
14. Bowen AL, Zomas A, Emmett E, Matures E, Dyer MJ, Catovsky D: Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br. J. Haematol. 96, 617-619 (1997).
15. Pawson R, Dyer MJ, Barge R et al.: Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J. Clin. Oncol. 15, 2667-2672 (1997).
16. Keating MJ, Flinn I, Jain V et al.: Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: results of a large international study. Blood 99, 3554-3561 (2002).
17. Hale G, Rebello P, Brettman LR et al.: Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104, 948-955 (2004).
18. Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G: Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 3, 261-267 (2001).
19. Dyer MJ: The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin. Oncol. 26, 52-57 (1999).
20. Montillo M, Tedeschi A, Miqueleiz S et al.: Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J. Clin. Oncol. 24, 2337-2342 (2006).
21. Osterborg A, Dyer MJ, Bunjes D et al.: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J. Clin. Oncol. 15, 1567-1574 (1997).
22. Rai KR, Freter CE, Mercier RJ et al.: Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol. 20, 3891-3897 (2002).
23. Cheson BD, Bennett JM, Grever M et al.: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87, 4990-4997 (1996).
24. Keating MJ, O'Brien S, Kontoyiannis D et al.: Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk. Lymphoma 43, 1755-1762 (2002).
25. Thornton PD, Gruszka-Westwood Am, Hamoudi RA et al.: Characterisation of Tp53 abnormalities in chronic lymphocytic leukaemia. Hematol J. 5, 47-54 (2004).
26. Stilgenbauer S, Kröber A, Busch R, Eichhorst B et al.: 17p deletion predicts for inferior overall survival after fludarabine - based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 trial of the GCLLSG. American Society of Hematology Annual Meeting Abstracts. Atlanta, GA, USA, 106, Abstract 715 (2005).
27. Lozanski G, Heerema NA, Flinn TW et al.: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103, 3278-3281 (2004).
28. Catovsky D, Richards S, Matutes E et al.: Response to therapy and survival in cll is influenced by genetic markets, preliminary analysis from the LRF CLL4 Trial. American Society of Hematology Annual Meeting Abstracts. San Diego, CA, USA Blood 104, 13 (2004).
29. Osuji N, Del Giudice I, Matutes E, Dearden C, Catovsky D: Alemtuzumab for chronic lymphocytic leukemia with and without p53 deletions. Session type: poster session 723-II. American Society of Hematology Annual Meeting Abstracts. San Diego, CA, USA; Blood 104, 2510 (2004).
30. Stilgenbauer S, Dohner H: Campath-1H-induced complete remission of chronic lythphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N. Engl. J. Med. 347, 452-453 (2002).
31. Stilgenbauer S, Winkler D, Kröber A et al.: Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL: interim analysis of the CLL2H Study of the German Cll Study Group (GCLLSG). American Society of Hematology Annual Meeting Abstracts. San Diego, CA, USA; Blood 104, 478 (2004).
32. Kennedy B, Rawstron A, Carter C et al.: Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99, 2245-2247 (2002).
33. Elter T, Borchmann P, Schulz H et al.: Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a Phase II trial. J. Clin. Oncol. 23, 7024-7031 (2005).
34. Rawstron AC, Kennedy B, Evans PA et al.: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98, 29-35 (2001).
35. Moreton P, Kennedy B, Lucas G et al.: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J. Clin. Oncol, 23, 2971-2979 (2005).
36. Keating MJ, O'Brien S, Albitar M et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4079-4088 (2005).
37. Bosch F, Ferrer A, Lopez-Guillermo A et al.: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br. J. Haematol. 119, 976-984 (2002).
38. Faderl S, Thomas DA, O'Brien S et al.: Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101, 3413-3415 (2003).
39. Lin TS, Flinn IW, Lucas MS et al.: Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia 19, 1207-1210 (2005).
40. Kanti RR, Nancy DJ, Crowley A, Ahmed S: Varying modes of maintenance therapy with Campath-1H in chronic lymphocytic leukemia (CLL). American Society of Clinical Oncology. Orlando, FL, USA; Proc. Am. Soc. Clin. Oncol. (2002).
41. Thieblemont C, Bouafia F, Hornez E et al.: Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leuk. Lymphoma 45, 711-714 (2004).
42. Kanti RR, Byrd JC, Peterson B, Gautier M, Larson RA: (2506) subcutaneous alemtuzumab following fludarbine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB Study 19901. American Society of Hematology Annual Meeting Abstracts. San Diego, CA, USA; Blood 102(11) Abstract 2506 (2003).
43. O'Brien SM, Kantarjian HM, Thomas DA et al.: Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98, 2657-2663 (2003).
44. O'Brien SM, Gribben JG, Thomas DA, Albitar M et al.: Alemtuzumab for minimal residual disease in CLL. American Society of Hematology Annual Meeting Abstracts. San Diego, CA, USA; Blood 102 (11) Abstract 371 (2003).
45. Wendtner CM, Ritgen M, Schweighofer CD et al.: Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter Phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18, 1093-1101 (2004).
46. Osterborg A. Fassas AS, Anagnostopoulos A et al.: Humanized CD52 monoclonal antibody CAMPATH-1H as first-line treatment in chronic lymphocytic leukaemia. Br. J. Haematol. 93, 151-153 (1996).
47. Hillmen P, Skotnicki A, Robak T, Jaksic B, Sirard C, Mayer J: Alemtuzumab (CAMPATH, MABCAMPATH) has superior progression free survival (PFS) vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL). American Society of Hematology Annual Meeting Abstracts. Orlando, FL, USA Blood 108, 301 (2006).
48. Hillmen P, Skotnicki A, Robak T et al.: Preliminary safety and efficacy report of randomized trial of alemtuzumab vs. chlorambucil as frontline in 297 patients with progressive B-CLL. Blood 104, 2505 (2004).
49. Keating M, Coutre S, Rai K et al.: Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin. Lymphoma 4, 220-7 (2004).
50. Thursky KA, Worth LJ, Seymour JF, Prince MH, Slavin MA: Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br. J. Haematol. 132, 3-12 (2006).
51. Lundin J, Porwit-MacDonald A, Rossmarm ED et al.: Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 18, 484-490 (2004).
52. Rawstron AC, Rollinson SJ, Richards S et al.: The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment Br. J. Haematol. 107, 148-153 (1999).
53. Faderl S, Coutre S, Byrd JC et al.: The evolving role of alemtuzumab in management of patients with CLL. Leukemia 19, 2147-2152 (2005).
54. Rawstron AC, Kennedy B, Moreton P et al.: Early prediction of outcome and response to alemtuzumab therapy in chromic lymphocytic leukemia. Blood 103, 2027-2031 (2004).
55. Ferrajoli A, O'Brien SM, Cortes JE et al.: Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98, 773-778 (2003).
56. Rai KR, MJ K, Coutze S: Patients with refractory B-CLL and T-PLL treated with alemtuzumab on a compassionate basis. Report of efficacy and safety of CAM 511 trial. American Society of Hematology Annual Meeting Abstracts. Philadelphia, PA, USA (2002).
57. Wierda W, Eaderl S,O'Brien S, Cortes J et al.: Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with Cll. American Society of Hematology Annual Meeting Abstracts. San Diego, CA, USA. Blood 104, 340 (2004).
58. Lundin J, Kimby E, Bjorkholm M et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (CAMPATH-1H) as first-line treatment for patients with B-cell chronic lymphocyctic leukemia (B-CLL). Blood 100, 768-773 (2002).